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Background: Sodium channels predominantly expressed in brain are expressed in myocardial tissue and play an
important role in cardiac physiology. Alterations of sodium channels are known to result in neurological disease
in infancy and childhood. It will be of interest to study the expression of brain-type sodium channels in the
developing myocardium.
Methods: The expression of neuronal sodium channels (SCN1A, SCN8A) and the cardiac isoform SCN5A in the
developing rat myocardium was studied by rtPCR, Western blot, and immunohistochemistry at different stages of
antenatal and postnatal development.
Results: Significant changes of sodium channel expression during development were detected. Whereas SCN5A
RNA increased to maximum levels on day 21 after birth, the highest SCN1A RNA levels were detected on day 1 to 7
after birth. SCN8A RNA was maximally expressed during embryonic development. At the protein level, the amount
of SCN5A protein increased along with the RNA level. SCN1A protein level decreased after birth in contrast to RNA
expression. Western blot could not detect SCN8A protein in the myocardium at any stage of development.
Immunohistochemistry however proved the presence of SCN8A protein in the developing rat myocardium.
Conclusions: Heart- and brain-type sodium channels are differentially expressed during ontogenesis. The high
expression level of SCN1A in the perinatal period and early infancy indicates its importance in preserving a regular
cardiac rhythm in this early phase of life. Altered regulation of sodium channels might result in severe cardiac
rhythm disturbances.
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Voltage-gated sodium channels (VGSCs) conduct the so-
dium current, responsible for the rapid initial upstroke
of the action potential in excitable cells [1,2]. To date, ten
different isoforms of the pore-forming VGSC α-subunit
have been described in the literature [3,4]. The quantita-
tive expression of each isoform varies between different
tissues [3]. SCN5A is the VGSC mainly expressed in the
heart. Besides cardiac-specific pore-forming VGSC α-
subunits, there is evidence that other forms of VGSC α-
subunits, which are mainly expressed in skeletal muscle* Correspondence: ukrause1@gwdg.de
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in any medium, provided the original work is pand neuronal tissue, are present in cardiac tissue [5-9]. Re-
cently, the functional relevance of myocardial expression
of other subtypes of VGSC, which otherwise are predom-
inantly expressed in neuronal tissue, has been shown [5,6].
Brain-type VGSC seems to play an important role in exci-
tation contraction coupling as well as in normal sinoatrial
node function [10,11]. To date, little is known about the
differential expression of voltage-gated sodium channel
gens in the developing myocardium. In neuronal tissue,
the differential expression of voltage-gated sodium chan-
nels during ontogenesis has been shown recently [12]. As
sodium channels play an important role in normal
brain development, it is reasonable to assume that the
same is true for normal myocardial development [13].
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as well as adult patients suggest developmental changes in
sodium current properties of cardiac myocytes [14].
However, data on the details of the developmental ex-
pression of VGSC and its regulation in the myocardium
are rare yet.
The aim of the present study was to elucidate the dif-
ferential expression of heart-type as well as brain-type
VGSC α-subunits during ontogenesis in the rat myocar-
dium on RNA and protein level in a quantitative approach.
As brain-type VGSC seem to play a crucial role for cardiac
rhythmogenesis within the sinuatrial node [11] and may
contribute to the etiology of sudden cardiac death in pa-
tients suffering from Dravet Syndrome, it was of interest
whether any of the analyzed VGSC genes shows predomin-
ant expression either within the ventricular or the atrial
myocardium.Table 1 Primers used
Gene Forward primer Reverse primer
SCN1A 5′ CCC ACC ACT CAG AAT
CTC ATA C 3′
5′ GGC TAT ACA TTG AAC
GTC ATC C 3′
SCN5A 5′ AGC CAC CAG TGA TAA
CCT C 3′
5′ CTG CAT AAG GTT CGT
CAG G 3′
SCN8A 5′ AAC TTC CGA ATC TCA
CGG ATG 3′
5′ GTG TGG AAC ATG CAG
TAA CCG 3′
AR 1† 5′ ATC CTG GTC ACA ATG
GGA TAC C 3′
5′ CCT ACG CTG AAT GCT
GAG TGA T 3′
Sequences of primers used for rtPCR. †Adiponectin receptor 1.Methods
Tissue samples
Cardiac and brain tissue was obtained from Wistar rats
(five animals/age group) of either gender raised according
to the guidelines for the care and use of laboratory animals
by the US National Institute of Health. The local institu-
tional Animal Care Committee (Georg August University,
Göttingen) had approved all procedures. The animals were
sacrificed by either decapitation (age 1 and 7 days) or
cervical dislocation (age 21 days and 6 weeks) according
to the local institutional animal care guidelines. Whole
hearts and brains were taken out quickly and frozen in
liquid nitrogen (Universal Industrial Gases, Easton, PA,
USA) for RNA extraction and for Western blot analysis.
At the developmental stages of 21 days and 6 weeks, atrial
myocardium was separated from the ventricles before fur-
ther processing. For preparation of embryonic tissue, preg-
nant rats were sacrificed by cervical dislocation on day 17
of gestation. Embryos were taken out of the uterus, and
whole hearts and brains were quickly excised and frozen
in liquid nitrogen for further procession.
For immunohistochemistry, whole hearts and brains were
fixated in formaldehyde (Merck & Co., Inc., Whitehouse
Station, NJ, USA) for 24 h. For immunohistochemistry
from embryonic tissue, whole embryos were fixated in for-
maldehyde for 24 h, respectively. After initial fixation, tis-
sue was divided into two halves according to the desired
direction of slicing and fixated with formaldehyde for an-
other 24 h.
Following fixation, tissue was embedded in paraffin
(Merck & Co., Inc., Whitehouse Station, NJ, USA) and sub-
sequently slices of 3-μm thickness were obtained using a
microtome (RM 2165, Leica Microsystems GmbH, Wetzlar,
Germany). The final slices were then further processed for
immunohistochemistry.RNA purification
After frozen tissue was pulverized in a mortar cooled in li-
quid nitrogen, RNA extraction was accomplished using
the peqGOLD TriFast™ reagent (PEQLAB Biotechnologie
GmbH, Erlangen, Germany). For RNA purification,
the RNeasy Mini Kit™ (Qiagen, Hilden, Germany) was
used. Extraction and purification of RNA were con-
ducted according to the manufacturer’s protocol. Puri-
fied RNA samples were stored at −80°C until further
processing.
RT-PCR and mRNA quantification
One microgram of RNA was transcribed into cDNA
using random hexamere primers and SuperScript® II Re-
verse Transcriptase (both Invitrogen™, Life Technologies
Corporation, Darmstadt, Germany) according to the
manufacturer’s instruction using a thermocycler (iCycler®,
Bio-Rad Laboratories GmbH, München, Germany). mRNA
expression was determined using SYBR®-green on a
TaqMan® sequence detector (Applied Biosystems®, Life
Technologies Corporation, Darmstadt, Germany). For
each gene, intron-spanning primer pairs were used in a
final concentration of 0.2 μM (sodium channel genes:
Biomers.net GmbH, Ulm, Germany; adiponectin recep-
tor 1 gene: Carl Roth GmbH, Karlsruhe, Germany).
Table 1 gives detailed information on the primers used.
TaqMan® cycling conditions were as follows: initially,
taq-polymerase was activated at 95°C for 15 min. There-
after, amplification cycle conditions were 30 s at 94°C,
30 s at 58°C, and finally 30 s at 72°C. Amplification cycles
were repeated for 40 times. After each run, a melting
curve analysis was performed to ensure amplification of
correct products. Sodium channel mRNA expression was
normalized for levels of the cardiac adiponectin receptor 1
as a housekeeping gene, which is stably expressed in car-
diac tissue at all developmental stages [15].
Membrane extraction
For membrane extraction, fresh tissue samples were
used according to the manufacturer’s protocol (Plasma
Membrane Protein Extraction Kit, BioVision, Mountain
View, USA).
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Frozen tissue was pulverized in a mortar as described
above. After suspending the powder in lysis buffer
(20 mM TRIS, 50 mM NaCl, 50 mM NaF, 4 mM Na-
pyrophosphate, 0.25 M sucrose, pH 7.4 ad 500 ml
ddH2O, 10 mM DTT, 1% TritonX-100, protease inhibitors
and phosphatase inhibitors; Sigma-Aldrich, Deisenhofen,
Germany), protein was precipitated by adding isopropanol
to the organic phase of the suspension. After incubation
at room temperature for 10 min, the precipitated proteins
were sedimented by centrifugation (10,000 × g, 10 min,
4°C). The supernatant was discarded and the protein
pellet was washed three times with ethanol containing
0.3 mM guanidine hydrochloride (20-min incubation at
room temperature, 20-min centrifugation at 10,000 × g,
4°C). After a further washing step with ethanol, the protein
pellet was dried in a vacuum centrifuge. The protein pellet
was dissolved in 1% SDS containing protease inhibitors
and phosphatase inhibitors (Sigma-Aldrich, Deisenhofen,
Germany). Final protein concentration was determined
using a commercially available kit (BCA Protein Assay
Kit, Thermo Fisher Scientific Inc., Waltham, MA, USA)
according to the manufacturer’s instructions.
A total of 30 to 120 μg cellular protein extract (glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) 30 μg,
SCN5A 50 μg, SCN1A and SCN8A 120 μg) per lane
were subjected to SDS-PAGE (14% polyacrylamide gel
and 4 % polyacrylamide gel, respectively). Gels were in-
cubated for 30 min at 37°C. Subsequently, proteins were
transferred to a nitrocellulose membrane and the mem-
brane was blocked in Tris-buffered saline (TBS) buffer
pH 7.6 containing 5% milk powder for 2 h at room
temperature. Incubation with the primary antibody was
performed overnight at 4°C in TBS buffer containing 1%
Tween and 5% milk powder. Primary antibody dilutions
were polyclonal rabbit anti-SCN1A, anti-SCN5A, anti-
SCN8A 1:200 (ASC-001, ASC-005, and ASC-009, respect-
ively; all AlomoneLabs, Jerusalem, Israel), and monoclonal
rabbit anti-GAPDH 1:2,000 (#2118, Cell Signaling Tech-
nology, Danvers, USA). HRP-conjugated secondary anti-
bodies (goat anti-rabbit Ig, BD Pharmingen, San Diego,
USA) were used in TBS buffer containing 1% Tween and
5% milk powder for 2 h at room temperature. The follow-
ing secondary antibody dilutions were used: SCN1A,
SCN5A, SCN8A 1:2,000, and GAPDH 1:10,000. Chemilu-
minescence was detected using Super Signal West Femto
reagent (Thermo Fisher Scientific Inc., Waltham, USA)
and a LAS 4000 mini imaging system (GE Healthcare,
Buckinghamshire, UK).
In order to evaluate the amount of proteins, the op-
tical density of the respective protein representing bands
was evaluated and normalized to the optical density of
the bands representing the housekeeping protein (Bio
Photometer®, Eppendorf AG, Hamburg, Germany).Immunohistochemistry
Tissues slices for immunohistochemistry were prepared
as described above. Paraffin slices were subsequently in-
cubated three times in xylol for 8 min before rehydration
was accomplished by rinsing with ethanol of decreasing
concentration (100%, 96%, 70%, 50%, and 30% for 8 min,
respectively). This step was followed by 8 min rinsing
with deionized water (all chemicals by Sigma-Aldrich,
Deisenhofen, Germany). Rinsing was followed by 20-min
incubation at 90°C. Following this procedure, tissue sam-
ples were washed 5 times with Tris-buffered saline and
Tween 20 (TTBS) and treated with DAKO peroxidase
blocking reagent for 17 min thereafter (RMR 662, Biocare,
Concord, CA, USA). Subsequently, they were rinsed with
TTBS for 5 min again. After incubation with Rodent Block
R blocking reagent (Biocare, Concord, CA, USA) and rins-
ing with TTBS, primary antibodies and substitution con-
trols were applied respectively and incubated overnight.
Antibody concentrations were 1:200 for SCN1A, 1:400 for
SCN5A, and 1:600 for SCN8A. The secondary antibody
(Rabbit on Rodent, Biocare, Concord, CA, USA) was pre-
incubated for 30 min with XR Factor (Biocare, Concord,
CA, USA) in a concentration of 1:76 in order to minimize
unspecific staining. After rinsing with TTBS and deionized
water, counterstaining with hemalaun was performed. Fi-
nally, water was extracted by incubation in 96% and 100%
ethanol and xylol for 1, 2, and 5 min, respectively.
Statistical evaluation
Results are expressed as mean percent change of mRNA
expression or protein amount ± standard deviation (SD)
compared to developmental stage E17 set at 100%.
Statistical analysis was performed using one-way analysis
of variance (ANOVA). Significance of differences was
established using a Tukey’s test for post hoc comparisons.
All statistical analysis was performed using GraphPad
Prism version 4.00 software (GraphPad Software Inc., La
Jolla, CA, USA). p values <0.05 were considered to be
significant, and p values <0.001 were assumed to be
highly significant.
Results
Differential mRNA expression of VGSC during development
Analysis of mRNA expression of VGSC in the develop-
ing rat myocardium revealed differential expression of
SCN1A, SCN5A, and SCN8A. A more than sixfold in-
crease of SCN1A mRNA expression was found immedi-
ately after birth (645 ± 13%, n = 5, p < 0.001). As describes
above, RNA expression at stage E17 was set to 100% as
a reference value for all genes analyzed at any develop-
mental stage. Whereas there was no significant change
in the amount of SCN1A mRNA until day 7 of life (602 ±
22%, n = 5), a significant drop of mRNA levels was ob-
served on day 21 (241 ± 14%, n = 5, p < 0.001, ventricular
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dium, respectively) and at the age of 6 weeks (356 ± 40%,
n = 5, p < 0.001, ventricular myocardium; 169 ± 43%, n = 5,
p < 0.05, atrial myocardium, respectively). Compared to
prenatal mRNA levels, however, SCNA1 expression was
still 1.5 to 3 times higher on day 21 and 6 weeks after birth
(Figure 1).
Analyzing mRNA the expression of SCN5A at differ-
ent stages of ontogenesis, the amount of SCN5A mRNA
significantly increased after birth to 201 ± 21% on day 1
(n = 5, p < 0.001), to 257 ± 30% on day 7 (n = 5, p < 0.001),
and to 353 ± 25% on day 21 (n = 5, p < 0.001), respectively.
This observation was similar to the results for SCN1A
mRNA in this study. A slight and non-significant drop to
289 ± 16% was found at the age of 6 weeks. However, this
amount of SCN5A mRNA was still significantly higher in
comparison with the prenatal mRNA amount at stage E17
(n = 5, p < 0.001, Figure 2).
In contrast to the aforementioned SCN1A and SCN5A
genes, mRNA expression of the second brain-type VGSC
SCN8A was highest at the embryonic stage of development
and consecutively dropped after birth to 34 ± 23% on day 1
of life, to 27 ± 15% on day 7 after birth, to 11 ± 20% on day
21, and finally reached a level of 8 ± 21% in the ventricular
myocardium of 6-week-old animals (Figure 3), respectively.
Differences of mRNA expression in ventricular vs. atrial
myocardium
In order to analyze the regional expression of VGSC
mRNA in the developing heart, we compared mRNA ex-
pression in the ventricular myocardium with mRNA ex-
pression in the atrial myocardium at the developmental
stages day 21 and 6 weeks. SCN1A and SCN5A mRNAE17 P 1 P 7
Figure 1 SCN1A mRNA expression. Expression of SCN1A mRNA increase
development. At the age 21 days and 6 weeks, respectively, mRNA express
significantly (*p < 0.05; **p < 0.01; #p < 0.001). E17, embryonic day 17 after g
postnatal day, ventricular myocardium; P21a., 21st postnatal day, atrial myo
6th postnatal week, atrial myocardium; P, protein level; R, mRNA level.expression was lower in the atria compared to ventricu-
lar myocardium (167 ± 32% atrial myocardium vs. 271 ±
14% ventricular myocardium of SCN1A at day 21, p <
0.05, n = 4; 169 ± 43% atrial myocardium vs. 356 ± 40%
ventricular myocardium of SCN1A after 6 weeks, p < 0.01,
n = 5; 287 ± 11% atrial myocardium vs. 353 ± 25% ven-
tricular myocardium of SCN5A at day 21, statistically not
significant; 196 ± 34% atrial myocardium vs. 289 ± 16%
ventricular myocardium of SCN5A after 6 weeks, statis-
tically not significant) whereas a higher expression of
SCN8A mRNA was found at the atrial site (23 ± 11%
atrial myocardium vs. 11 ± 20% ventricular, myocardium
at day 21, p < 0.001, n = 5; 12 ± 37% atrial myocardium
vs. 8 ± 21% ventricular myocardium after 6 weeks, p <
0.001, n = 5; Figures 1, 2, and 3, Table 2).
Differential expression of VGSC protein in the developing
rat heart
In order to determine the levels of SCN1A, SCN5A, and
SCN8A protein (Nav1.1, Nav1.5, and Nav1.6, respectively),
Western blot analysis was performed from samples of rat
myocardium at the same developmental stages as PCR
analysis had been conducted. In contrast to distribution of
mRNA expression of SCN1A throughout ontogenetic de-
velopment, SCN1A protein levels were highest during the
embryonic stage of development and initially decreased
slightly at day 1 of life (91 ± 47%). On day 7, a further de-
crease of protein amount of SCN1A was observed (65 ±
43%). Both changes, however, did not reach statistical sig-
nificance compared to developmental stage E17 (n = 3).
After 21 days and 6 weeks of life, SCN1A protein
amount dropped significantly to 56 ± 38% (ventricular
myocardium, day 21), to 57 ± 39% (atrial myocardium,W 6 v. W 6 a.P 21 a.P 21 v.
d dramatically after birth and declined significantly with postnatal
ion in the ventricular myocardium exceeded atrial expression
estation; P1, 1st postnatal day; P7, 7th postnatal day, P21v., 21st
cardium; W6v., 6th postnatal week, ventricular myocardium; W6a.,
E17 P 1 W 6 v. W 6 a.P 21 a.P 21 v.P 7
Figure 2 SCN5A mRNA expression. Expression of SCN5A mRNA steadily increased after birth compared to the embryonic level of development.
The slight drop of mRNA expression after day 21 was not significant. Significance refers to the amount of mRNA on day 17 of embryonic development
(Abbreviations and levels of significance as depicted in Figure 1).
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to 51 ± 35% (ventricular myocardium 6 weeks, p < 0.01,
n = 3), and to 43 ± 29% (atrial myocardium 6 weeks, p >
0.001, n = 3, Figures 1 and 4).
Whereas the protein amount and mRNA expression of
SCN1A differed profoundly during development, SCNA5A
protein amount almost paralleled mRNA expression. On
day 1 and day 7 of postnatal life, SCN5A protein amount
increased to 188 ± 127% and 202 ± 160% compared to de-
velopmental stage E17. On day 21 and after 6 weeks, a fur-
ther increase in protein amount of ventricular myocardium
was observed (284 ± 140% and 232 ± 81%, respectively).E17 P PP 7
Figure 3 SCN8A mRNA expression. Highest expression of SCN8A mRNA
birth. Lowest levels of SCN8A mRNA were measured at age 6 weeks (AbbrLower levels of SCN5A protein were detected in atrial
myocardium after 21 days and after 6 weeks of life (102 ±
66% and 109 ± 58% respectively). Developmental differ-
ences of SCN5A protein amount at various developmental
stages as detected however failed to reach statistical signifi-
cance (n = 3, Figure 2).
Whereas mRNA of SCN8A was readily detectable at
all developmental stages, Western blot analysis from
cardiac tissue failed to detect SCN8A protein at all. In
rat brain tissue, however, SCN8A protein (NaV 1.6) was
easily detectable using an identical Western blot proto-
col (Figure 5).W 6 v. W 6 a.P 21 a. 21 v.
was observed on day 17 of gestation and progressively declined after
eviations and levels of significance as depicted in Figure 1).
Table 2 SCN1A, SCN5A, and SCN8A expression
P21 W6
Gene Atrium Ventricle p Atrium Ventricle p
SCN1A 167 ± 32% 271 ± 14%* < 0.05 169 ± 43% 356 ± 40%* <0.01
SCN5A 287 ± 11% 353 ± 25% n.s. 196 ± 34% 289 ± 16% n.s.
SCN8A 23 ± 11% 11 ± 20%* < 0.001 12 ± 37% 8 ± 21%* <0.001
Differential expression of VGSC within the atrial as well as the ventricular myocardium at postnatal developmental stages of 21 days (P21) and 6 weeks (W6).
Significant differences are marked by an asterisk (*).
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In order to verify the presence of SCN8A protein in the
developing rat myocardium, we used an immunohisto-
chemical approach to detect SCN8A protein in cardiac
tissue. As depicted in Figure 6, SCN8A protein was
detectable at the developmental stages P1, P7, and W6
postnatally. In tissue samples from 6-week-old animals,
we found a quite strong signal in the atrial myocardium
compared with ventricular myocardium, suggesting a pre-
dominantly atrial expression of SCN8A protein at this
stage of development.
Discussion
In previous studies, presence of other than the “cardiac-
specific” VGSC had been suspected by the fact that tetro-
dotoxin (TTX) had been shown to impair left ventricular
function. VGSC isoforms preferentially expressed in cen-
tral nervous tissue are inhibited by nanomolar concentra-
tions of TTX, whereas the cardiac isoform SCN5A is
inhibited only by micromolar concentrations of TTX and
is therefore considered to be TTX-resistant [4]. In the
present study, we were able to prove the expression of
brain-type VGSC in the developing rat myocardium. The
expression of the cardiac VGSC SCN5A and brain-type
VGSC SCN1A and SCN8A was regulated differentially
in the developing rat myocardium. Differential expres-
sion was demonstrated on RNA level as well as on pro-
tein level.
The differential expression of VGSC genes in cardio-
myocytes has been shown in a recent study [13]. How-
ever, this study did not quantitatively measure the
expression of VGSC α-subunit protein but was restrictedE17 P 1 P 7
Figure 4 Analysis of SCN1A protein expression. In contrast to rtPCR res
progressive decline with postnatal development (upper panel). As a control
(lower panel; abbreviations as depicted in Figure 1).to quantitative PCR and immunocytochemistry, a non-
quantitative method. It is well known that posttranscrip-
tional as well as posttranslational modification regulates
the amount of functional VGSC protein in the plasma
membrane of excitable cells. Mechanisms like microRNA
and protein phosphorylation as well as dephosphorylation
probably play a crucial role in such processes [16-19].
Focusing on the time course of VGSC expression in
different tissues, it is an interesting finding that in the
central nervous system, the differential expression of
SCN1A protein has been described to follow a distinct
time course. The expression of SCN1A protein in brain
tissue was found to steadily increase from birth until the
age of 7 months. However, the time course of differential
expression in central nervous tissue differs from what
we found in myocardial tissue [12]. This obviously might
be a result of different laboratory agents and primers used
in the present and in the quoted study. However, different
demands of cardiomyocytes vs. central nervous neurons
should also be taken into consideration to explain the ob-
served differences. The different results may therefore be
explained by either different posttranslational modification
of SCN1A protein in brain tissue or blockade of SCN1A
translation by microRNA. Future studies on pre- and
posttranslational processing of SCN1A are required to
elucidate the underlying mechanisms of this phenomenon.
It is well known that adrenergic stimulation of the heart
influences not only gating kinetics of myocardial VGSC
but also the amount of VGSC and their distribution
within the plasma membrane of the cardiomyocytes [20].
Since a differential developmental expression has been
shown for adrenergic receptors in the developing heart asW 6 v. W 6 a.P 21 a.P 21 v.
ults, Western blot analysis of SCN1A protein expression showed a
, protein expression of GAPDH showed no changes with development
Figure 5 Analysis of SCN8A protein expression. SCN8A protein could not be found all in cardiac tissue of any developmental stage. However,
a typical band slightly above 250 kDa was found in a Western blot from brain tissue of 6-week-old animals (arrow; abbreviations as depicted
in Figure 1).
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the regulation of myocardial VGSC expression may be an-
ticipated and needs further investigation.
A loss of function mutation of SCN1A has been linked
to an epilepsy disorder called Dravet Syndrome (DS).Figure 6 SCN8A specific immunohistochemistry from tissue
samples of different developmental stages (A = P1, B = P7,
C =W6). At developmental stage W6, staining of the atrial myocardium
(asterisk) was more intense compared with ventricular myocardium (o).This disease usually manifests within the first year of life
and patients with DS are prone to develop sudden car-
diac death [24-26]. The differential SCN1A expression in
rat myocardium might influence the susceptibility for
sudden cardiac death in these children at different ages,
since higher incidence of sudden death at young ages in
patients with epilepsy has been described in multiple
studies [27-30]. In order to further investigate the role of
SCN1A in sudden death in infants and children and to
elucidate the role of cardiac SCN1A in this setting, it
would be worthwhile to study the electrical properties of
an SCN1A knockout animal. Such animals have been
established [31] but characterization of the electrical
properties of the animal cardiomyocytes is still lacking.
As SCN1A is highly expressed within the SA node in
mice and therefore might play an important role in nor-
mal rhythmogenesis [11], a higher amount of SCN1A
gene product at earlier developmental stages has been
suggested to be responsible for the physiologically higher
heart rate at younger age [13].
In order to address the question whether other than
cardiac-specific TTX-resistant VGSC are expressed in
myocardial tissue, previous work suggested the absence of
TTX- and saxitoxin (STX)-sensitive receptors in fetal and
neonatal myocardium. The appearance of high-affinity
STX and TTX receptors has been shown at later stages of
development in cardiac tissue [5,32]. Our results showed a
drop of SCN1A as well as SCN8A gene expression after
birth, which is in contrast to the results of the studies
mentioned before since SCN1A and SCN8A represent
TTX-sensitive VGSCs. This may be explained by the fact
that skeletal muscle VGSC conduct a high proportion of
TTX-sensitive sodium current in cardiomyocytes, and
previous studies did not differentiate between VGSC
isoforms [5,13,32]. The differential expression of skel-
etal muscle VGSC however was not analyzed in the
present study.
The expression of SCN8A RNA was highest at the em-
bryonic stage of development and decreased progressively
after birth. These results are in accordance with the obser-
vation of Haufe et al. [13] demonstrating a similar devel-
opmental SCN8A RNA expression pattern in mouse
myocardium. In the present study, however, we were not
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analysis. This finding may be due to very small amounts
of protein in cardiomyocytes. In order to rule out a
methodical error resulting in failure of SCN8A protein
detection in the developing rat myocardium by Western
blot, we were able to quantify the expression of SCN8A
protein from brain samples with an identical experi-
mental setup (Figure 5). In order to prove expression of
SCN8A protein in cardiomyocytes, we were able to de-
tect SCN8A protein in rat cardiomyocytes of different
developmental stages by means of immunocytochem-
istry. Quantification of SCN8A protein expression was
therefore not possible. At a later developmental stage,
we found a more intense labeling for SCN8A protein in
the atrial than in the ventricular myocardium, indicating
an important role of SCN8A in atrial sodium current
conductance. Assuming that protein expression of SCN8A
follows RNA expression as has been shown for SCN5A in
the present study, the quantification of differential SCN8A
protein expression would be of interest. A higher expres-
sion of SCN8A during ante- as well as early postnatal
stages of development might indicate an important role of
SCN8A ensuring proper action potential propagation
throughout atrial cardiomyocytes during early develop-
ment and a shift to other VGSC at later developmental
stages and during adulthood.
The developmental expression of the cardiac-specific
VGSC SCN5A mainly followed the expected pattern with
an increasing amount of RNA as well as protein with on-
going postnatal development. In contrast to SCN1A, ex-
pression of RNA and protein paralleled each other. Since
SCN5A is the main VGSC expressed in the myocardium
and therefore carries the biggest workload, it seems quite
reasonable for the cardiomyocyte not to ‘waste’ RNA or
channel protein but to express it as functional channel
protein within the cellular membrane.
Besides tissue- and cell-specific regulation of ion chan-
nel expression, external factors like hypoxemia or glucose
depletion have been shown to influence the expression of
cardiac ion channels [33,34]. Therefore, as neither oxygen
saturation nor glucose levels of the animals were moni-
tored before they were sacrificed, one cannot entirely
rule out such external factors influencing the amount of
RNA and protein in the present study, although it seems
unlikely.
Likewise, a certain ‘contamination’ of RNA and protein
levels of SCN1A and SCN8A by afferent cardiac nerve
fibers cannot entirely be ruled out. However, we are
quite confident that most of the RNA and protein we
found was derived from cardiomyocytes since immuno-
staining in cardiomyocytes was positive for both proteins
at different developmental stages and nerve fibers within
the myocardium (PGP 9.5 positive) stained only margin-
ally for VGSC.Conclusion
VGSC are differentially expressed in the developing rat
myocardium. The present study proved a differential ex-
pression not only of RNA but also of VGSC α-subunit
protein. Future studies are needed to elucidate the regu-
latory mechanisms of this phenomenon. Since VGSC
ß-subunits are of relevance for the functional properties
of VGSC, it will be of interest to study potential expres-
sion changes of these regulating ß-subunits in futures
studies. Furthermore, not only VGSC but also other ion
channels may be expressed differentially throughout de-
velopment. The ontogenic expression profiles of other
cardiac ion channels like potassium and calcium chan-
nels need to be studied in the future.
Limitations
The present study was focused on gaining more infor-
mation on the quantitative changes of myocardial VGSC
expression on RNA level as well as on protein level.
However, the informative value of atrial vs. ventricular
expression is limited by the fact that RNA and protein
levels were measured separately for the atria and the ven-
tricles only at the age of 21 days and 6 weeks and not at
earlier developmental stages. It will be the purpose of fu-
ture studies to elucidate the regulatory mechanisms of this
phenomenon. Comparing our data with the results from
other studies, an impact of different laboratory agents and
different primers cannot be ruled out and may explain at
least some of the differences found. In the present study,
we did not examine changes of membrane sodium current
conducted by the ion channels at different stages of myo-
cardial development. Functional testing, however, will be of
interest to understand the impact of differential ion chan-
nel expression on myocardial excitation. Therefore, elec-
trophysiological studies of myocardial membrane current
properties at different developmental stages may help to
improve our understanding. Finally, the present study was
conducted on rodents and results may therefore not apply
to humans.
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